Day: August 7, 2020

AS Tallinna Sadam invites all the stakeholders to join its investor conference webinar, introducing the results for Q2 and 6 months of 2020. The webinar is scheduled for 14 August 2020 at 11.00 am EET and will be held in English.The Chairman of the Management Board Valdo Kalm and Chief Financial Officer Marko Raid will be presenting the results and answering the questions. The questions will be answered after the presentation. Due to limited webinar time, we encourage participants to send their questions beforehand to e-mail: m.zirel@ts.ee .Participating in the webinar:To join the webinar, please click hereWhen joining the webinar for the first time, you will be asked to download the plug-in which will take only a few seconds. In case plug-in can’t be downloaded, a web browser which enables attending the webinar, opens automatically.Registered...

AS Tallinna Sadam kutsub huvilisi osalema ettevõtte 2020. a II kvartali ja 6 kuu majandustulemusi tutvustaval veebiseminaril 14. augustil 2020 kell 11.00 EET. Veebiseminar toimub inglise keeles.Ettevõtte tulemusi tutvustavad ja küsimustele vastavad juhatuse esimees Valdo Kalm ja juhatuse liige/ finantsjuht Marko Raid. Küsimustele vastamine toimub peale esitlust. Kuna veebiseminari aeg on piiratud, soovitame küsimused saata enne veebiseminari algust e-mailile: m.zirel@ts.ee.Veebiseminaril osalemine:Veebiseminaril osalemiseks saab registreeruda siinTeile saadetakse link veebiseminarile ning juhised keskkonna kasutamiseks. Kui osalete veebiseminaril esimest korda, palutakse alla laadida vajalik rakendus. Juhul kui rakenduse allalaadimine ei õnnestu, avaneb automaatselt veebibrauser, mis võimaldab veebiseminari kuulata.Osalejatele saadetakse...

– Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 –– On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in 2020 –– Ended the quarter with $127.2 million in cash, cash equivalents and investments –– Company to host conference call and webcast today at 8:00 AM ET –CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.“We made great strides in the second quarter and this year as a whole has proven to be a time of execution and important...

SUNNYVALE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading provider of customer engagement solutions, today announced that management will participate in a fireside chat at the Oppenheimer 23rd Annual Technology, Internet & Communications virtual conference on Tuesday, August 11, 2020 at 1:00pm ET and will be available for one-on-one meetings with investors throughout the day on August 11th and 12th.For additional information or to schedule a meeting with eGain management, please contact either your Oppenheimer representative, or MKR Investor Relations, eGain’s investor relations firm, at egan@mkr-group.com.To access a live webcast or replay of the fireside chat, visit the investor relations section of eGain’s website at http://www.egain.com/company/investors/.About eGaineGain customer engagement...

OSLO, NORWAY (7 August 2020) – TGS hereby invites you to participate at a conference call and Q&A session for analysts and investors related to offer to acquire the multi-client data library of PGS, announced 6 August 2020.Time: 7 August 2020 at 15:00 CESTPresenter: Kristian Johansen, CEODial-in details:PIN Code for all countries: 938720Norway: + 47-21-956342Sweden: +46-8-1241-0952Denmark: +45 7876 8490UK: +44-203-7696819USA: +1 646-787-0157Please dial in 5-10 minutes prior to the call to ensure that you will be connected in time.For further information, please contact: Sven Børre LarsenHead of Business Development and M&ATel: +47 909 43 673E-mail: sven.larsen@tgs.com Fredrik AmundsenCFOTel: +47 995 89 882E-mail: fredrik.amundsen@tgs.com About TGS TGS-NOPEC Geophysical Company ASA (TGS) provides multi-client geoscience data...

Die globale Phase-II/III-Studie zu Opaganib soll bis zu 270 Patienten mit schwerem COVID-19 an 40 Prüfzentren aufnehmen.—Die globale Phase-II/III-Studie wurde in Mexiko, Großbritannien und Russland genehmigt und wird auch in Italien, Brasilien und weiteren Ländern geprüft.—Die Aufnahme in eine parallele Phase-II-Studie mit Patienten mit schwerem COVID-19 in den USA ist zu etwa 50 % fortgeschritten und wird voraussichtlich in diesem Monat abgeschlossen.—Mögliche Einreichung weltweiter Anträge für den Notfalleinsatz bereits für das vierte Quartal 2020 geplantTEL-AVIV (Israel) und RALEIGH, NC (USA), Aug. 07, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) („RedHill“ oder das „Unternehmen“), ein spezialisiertes biopharmazeutisches Unternehmen, hat heute die Genehmigung seines CTA-Antrags (Clinical Trial...

ST. LOUIS, Aug. 07, 2020 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced it will attend the following investor conferences during fourth quarter of fiscal 2020:Additional details to be available at https://investors.amdocs.com.Supporting ResourcesLearn more about Amdocs Investor RelationsKeep up with Amdocs news by visiting the company’s websiteSubscribe to Amdocs’ RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTubeAbout AmdocsAmdocs’ purpose is to enrich lives and progress society, using creativity and technology to build a better connected world. Amdocs and its 25,000 employees partner with the leading players in the communications and media industry, enabling next-generation experiences in 85 countries. Our cloud-native,...

FondeEUR CLO Opportunity, ACAECO, DK0060804052EUR CLO Inv. Grade, ACACIGDKK, DK0060804136Hermed offentliggøres ajourførte dokumenter med investorinformation for ovennævnte afdelinger.Det tidligere samlede dokument for begge afdelinger er delt i ét dokument for hver afdeling. Ændringerne i vedtægterne, som vedtget på ekstraordinær generalforsamling den 27. juli 2020 er indarbejdet.Herudover er der sket korrekturmæssige tilpasninger.Kontaktperson:Direktør Caspar Møller, tlf. +45 3332 7070.Yderligere oplysninger om Kapitalforeningen Accunia Invest findes på www.accunia-invest.dk.Attachments§62-dok – EuroCLO.IG – AccInvKF (aug’20)§62-dok – EuroCLO.OPP – AccInvKF (aug’20)

See attached presentation.AttachmentFesti hf. – Presentation of Q2 2020 results

–Completed all merger and integration activities in Q2––Repaid $10 million of Senior Secured Notes ahead of schedule––Zyla products partially contributed to Q2 net product sales of $20.2 million––Combined second quarter 2020 net product sales of $27.7 million, on a pro forma basis, increased modestly over pro forma first quarter 2020 despite COVID-19 and merger integration–LAKE FOREST, Ill., Aug. 07, 2020 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. During the second quarter, Assertio completed its merger with Zyla Life Sciences (“Zyla”).“Even in what has been an unprecedented time with patient volume and elective surgeries...